ReviewCancers2022

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.

Carlo Cattrini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.